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Abstract
Transcription factor mediated lineage reprogramming of human pancreatic exocrine tissue
could conceivably provide an unlimited supply of islets for transplantation in the treatment of
diabetes. Exocrine tissue can be efficiently reprogrammed to islet-like cells using a cocktail
of transcription factors: Pdx1, Ngn3, MafA and Pax4 in combination with growth factors. We
show here that overexpression of exogenous Pax4 in combination with suppression of the
endogenous transcription factor ARX considerably enhances the production of functional
insulin-secreting β-like cells with concomitant suppression of α-cells. The efficiency was fur-
ther increased by culture on laminin-coated plates in media containing low glucose concen-
trations. Immunocytochemistry revealed that reprogrammed cultures were composed of
~45% islet-like clusters comprising >80%monohormonal insulin+ cells. The resultant β-like
cells expressed insulin protein levels at ~15–30% of that in adult human islets, efficiently
processed proinsulin and packaged insulin into secretory granules, exhibited glucose
responsive insulin secretion, and had an immediate and prolonged effect in normalising
blood glucose levels upon transplantation into diabetic mice. We estimate that approxi-
mately 3 billion of these cells would have an immediate therapeutic effect following engraft-
ment in type 1 diabetes patients and that one pancreas would provide sufficient tissue for
numerous transplants.
Introduction
Type 1 diabetes results from the autoimmune destruction of the insulin-producing pancreatic
β-cells that are localised in islets of Langerhans. The most common form of treatment is the
exogenous supply of insulin, which efficiently reduces blood glucose levels but is unable to
mimic the tight glycaemic control provided by endogenous hormone production as there is no
glucose-insulin feedback control. This may lead to the development of further complications,
including life-threatening hypoglycaemia. The development of the Edmonton protocol repre-
sented a landmark in the treatment of type 1 diabetes, by establishing that transplantation of
isolated cadaveric islets provides much superior glycaemic control and prolonged insulin
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independence [1]. The wide application of this cell therapy is, however, limited by the shortage
of available donor islets. Thus, several strategies have been devised aimed at generating a
replenishable supply of β-cells for transplantation. These include derivation of β-cells from plu-
ripotent cells [2–11], and a variety of adult tissues that includes liver [12–15], and exocrine
pancreas [16–33].
We have previously shown that human exocrine tissue that is left over from the islet isola-
tion procedure can be reprogrammed towards insulin producing cells ex vivo, using a combina-
tion of the four pancreatic transcription factors (TFs) Pdx1, MafA, Ngn3 and Pax4 in
combination with the small molecules betacellulin, exendin-4 and nicotinamide. Crucially,
generation of β-like cells was dependent upon suppressing the epithelial to mesenchymal tran-
sition (EMT) that the exocrine tissue undergoes when placed in culture [34,35]. The resultant
cell population secreted insulin in response to glucose at concentrations within the physiologi-
cal range, and prevented the onset of diabetes when implanted in a diabetic mouse model [30].
In the present study we report the generation of mature, functional and clinically relevant β-
cells from human exocrine pancreas. The major finding was that knockdown of endogenous
ARX expression resulted in improved β-cell lineage specification. The resultant β-like cells
exhibited many of the properties of fully differentiated adult β-cells, expressed insulin at thera-
peutically significant levels, processed insulin in a similar manner to adult β-cells, were glucose
responsive, and contained insulin-secretory granules. Importantly, these β-like cells released
insulin into the blood stream and were able to normalise blood glucose levels shortly after
transplantation into diabetic mice.
Materials and Methods
Preparation of human exocrine pancreatic fractions
All human tissue was procured with written informed consent from the donor or next of kin
and with ethical approval from the North of Scotland and Chelsea Research Ethics Committees
(REC reference numbers 10/S0802/12 and 15/LO/2206). Human islets were isolated from
brain-dead adult donor pancreata at the Scottish Islet Isolation Laboratory, Edinburgh, UK,
under GMP conditions. For the five donors used in this study (3 males and 2 females) the
mean donor age was 35.6 ± 8.5 years (range 23–44 years) and BMI 29.4 ± 4.4 kg/m2 (range
25.6–30.4 kg/m2). The left over, exocrine enriched fraction, was immediately transported to the
reprogramming laboratory (typically within 8–10 h), where an aliquot was stained for insulin
with dithizone. Islets present within the partially digested exocrine tissue represented less than
1% (0.9 ± 0.3%, n = 5 preparations) of the total tissue. This exocrine-enriched fraction was
then cryopreserved in 90% foetal bovine serum (FBS, Gibco, Life Technologies, Paisley, UK)
and 10% DMSO (Sigma Aldrich, Dorset, UK) at a density of 300,000 exocrine clusters per vial.
Reprogramming human exocrine pancreatic fractions
Exocrine tissue was plated at a density of 4000 clusters per well on a 6-well plate and cultured
for two days in RPMI 1640 (Gibco, Life Technologies) supplemented with 10% foetal bovine
serum (FBS), 10 mMHEPES and 1 mM sodium pyruvate (all from Gibco). After 48 h, the clus-
ters adhered to the culture surface forming a monolayer of 1–2 x 105 cells per well. These cells
were subsequently cultured in serum free medium (SFM, RPMI 1640, 1% BSA (Sigma) and
insulin-transferrin-selenium (Gibco)) supplemented with 1 μM 5-aza-2'-deoxycytidine, 1 mM
sodium butyrate, 10 μM SB431542 and 2 μMY27632 for 3 days. On day 4 the cells were trans-
duced with replication-deficient adenoviruses encoding mouse Pdx1, Ngn3, MafA and Pax4, at
a multiplicity of infection (MOI) of 25 each. The cells were then cultured in SFM supplemented
with 1 nM betacellulin (Tocris, Bristol, UK), 10 nM exendin-4 (Sigma) and 10 mM
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nicotinamide (Sigma) for an additional 6 days, as previously described (Fig 1A and [30]). For
screening of additional TFs replication-deficient adenoviruses encoding mouse NeuroD and/or
Nkx6.1 were added at day 4, at an MOI of 25 each (Fig 1A and 1B).
Preparation of adenoviruses
Recombinant adenoviruses encoding the mouse sequences of Pdx1, MafA, Ngn3, Pax4, Neu-
roD and Nkx6.1 [27] were prepared using the Ad-Easy system (Agilent Technologies, Edin-
burgh, UK). Transduction was performed in serum free RPMI for 4h at a multiplicity of
infection (MOI) of 25 for each virus.
Quantitative Reverse Transcription Polymerase Chain Reaction (RT-
qPCR)
RT-qPCR was performed as previously described [30]. The TaqMan probes used are listed in
S1 Table. Data were analysed using the 2-ΔCT method [36].
siRNA-based knockdown
Knockdown of ARX in reprogrammed cells was performed by transfection in SFM with a pool
of four specific targeting small inhibitory RNAs, or scrambled controls (Dharmacon, Lough-
borough, UK), using the transfection reagent Dharmafect 1 (Dharmacon), at days 6 (Fig 2A) or
3 (Fig 3C) of the protocol.
Immunocytochemistry and immunohistochemistry
Immunostaining was performed as previously described [9], using the antibodies listed in S2
Table.
Hormone content
Cells were washed in PBS and resuspended in 70 μl 0.1 M KH2PO4 (pH 7.8). Cells were lysed
by three 30s freeze-thawing cycles. Supernatants were analysed using specific ELISAs for
human insulin, C-peptide and proinsulin (all fromMercodia, Uppsala, Sweden) and glucagon
(BD biosciences, Oxford, UK). Total protein was quantified using a protein assay (Biorad,
Hemel Hempstead, UK).
C-peptide release
Cells were washed in PBS followed by 90 min incubation in Krebs Ringer-bicarbonate Hepes
(KRHB) buffer containing 0.1 mM glucose. The cells were subsequently incubated for 90 min
with KRHB buffer containing the indicated glucose concentrations, and where indicated, 0.5
mM diazoxide (Sigma) or 0.2 mM tolbutamide (Sigma). Media were analysed with a specific
ELISA for human C-peptide (Mercodia).
Transmission electron microscopy
Cells were detached from plates using Accutase (BD Biosciences, Oxford, UK) and fixed in
2.5% glutaraldehyde in 0.1M sodium cacodylate buffer at 4°C overnight. Cells were post-fixed
with 1% osmium tetroxide for 1 h followed by embedding in epoxy resin and dehydrated in a
series of ethanol washes for 20 min, followed by embedding in epoxy resin, placing into
moulds, and polymerised at 65°C for 48 h. Sections were taken between 75 and 90 nm on a
Leica Ultracut E (Leica, Wetzlar, Germany) and placed on formvar/carbon grids. For
Generation of Functional Beta-Like Cells from Human Exocrine Pancreas
PLOS ONE | DOI:10.1371/journal.pone.0156204 May 31, 2016 3 / 19
Generation of Functional Beta-Like Cells from Human Exocrine Pancreas
PLOS ONE | DOI:10.1371/journal.pone.0156204 May 31, 2016 4 / 19
immunogold labeling, cells were fixed in 0.2% glutaraldehyde and 2% paraformaldehyde. Sec-
tions were placed on nickel grids and stained using mouse anti-insulin (1:200, Sigma) and
binding was identified using a goat anti-mouse protein A gold conjugate (1:40, 10 nm labels,
Aurion, Wageningen, Netherlands). Images were observed on a JEOL JEM-1400 Plus TEM,
and captured using an AMT UltraVue camera (Woburn, MA, USA).
Animal studies
All animal experiments were performed under UK Home Office regulations (Project License
60/4242) and with the approval of the University of Aberdeen Animal Welfare and Ethical
Review Body. Male 8–10 week old Scid/Beige mice (C.B.17/IcrHsd-Prkdcscid/Lystbg-J) were
obtained from Harlan Laboratories (Blackthorn, UK) and maintained on a 12 h light/dark
cycle with ad libitum access to a standard irradiated diet (Harlan Laboratories). Mice were
fasted for 4 h before rendered diabetic by three intraperitoneal injections of 75 mg/kg strepto-
zotocin (STZ) on consecutive days. Five million cells were grafted under the left kidney capsule
as previously described [9]. A glucose tolerance test was performed following an intraperitoneal
injection of 2 mg/kg D-glucose (after 4h fasting). All animals subjected to a subcapsular kidney
transplant and nephrectomy procedures were anesthetized with a mixture of isofluorane and
oxygen. Analgesia (0.1mk/kg Buprenorphine) was used before and following the procedures to
minimise pain. Body temperature was kept at 37°C throughout the procedure to minimise dis-
comfort. At the end of the experiment all animals were sacrificed by cervical dislocation.
Results
Transcription factor-mediated reprogramming of pancreatic exocrine
tissue
We have previously shown that the human exocrine tissue, obtained as a by-product of the
islet isolation procedure, can be reprogrammed towards insulin producing β-like cells [30].
The exocrine tissue is plated on tissue culture dishes for 48h to form a monolayer. The cells
then undergo an epithelial to mesenchymal transition (EMT) [37] over a period of days with
rapid loss of insulin (endocrine) and amylase (acinar). Interestingly, as previously reported
[25], the acinar cells dedifferentiate via an intermediate that co-expresses amylase and CK19.
Our previous in vitro genetic lineage tracing studies confirmed that the few residual β-cells and
acinar cells contribute to the resultant mesenchymal stromal cell (MSC) population [30]. This
MSC population expresses characteristic cell surface markers, can be differentiated towards
osteogenic, chondrogenic and adipogenic lineages, and repeatedly passaged. We reported pre-
viously [30] that efficient reprogramming towards β-cells was dependent on inhibiting EMT
using the TGFβ inhibitor SB431542 (SB) and the Rho kinase (ROCK) inhibitor Y27632 (Y2).
Sodium butyrate (NaBu) and Aza-2’deoxycytidine (Aza) were also included to modulate the
Fig 1. NeuroD and Nkx6.1 overexpression does not enhance reprogramming towards β-cells. (A) Schematic
representation of the reprogramming protocol. (B) Schematic representation of the various transcription factor (TF)
combinations analysed during the reprogramming protocol. (C) RT-qPCR analysis of the three main endocrine hormones
insulin (INS), glucagon (GCG) and somatostatin (SST) after reprogramming with each TF combination. Expression was
normalised to glyceraldehyde 3-phosphate dehydrogenase. (D) Release of human C-peptide to the culture medium by
untreated (N/A) and reprogrammed cells treated with the TF combinations that induced higher insulin expression levels. The
culture medium was harvested after 90 min incubation in 2.5 mM or 20 mM glucose. (E)RT-qPCR analysis of pancreatic
endocrine transcription factors in untreated (N/A) or reprogrammed cells treated with the TF combinations that induced higher
insulin expression levels. Expression was normalised to glyceraldehyde 3-phosphate dehydrogenase. Data are representative
of triplicate experiments and are represented as mean + standard error of the mean. A one way ANOVA was performed
followed by a Dunnet post hoc test to compare all treatment groups with the control group (N/A), where ***P < 0.001,
** P <0.01, *P < 0.05.
doi:10.1371/journal.pone.0156204.g001
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chromatin structure (Fig 1A). A detailed time course analysis showed that there was no detect-
able insulin by RT/qPCR (S1A Fig) or immunocytochemistry (S1B Fig) when the cells were
cultured for 72 h in the presence of these reagents, i.e. they did not induce selective retention
and proliferation of β-cells. After 72h the cells were transduced with adenoviruses containing
Pdx1, MafA, Ngn3 and Pax4 (4TFs) and cultured for 7 days in media supplemented with beta-
cellulin, exendin-4 and nicotinamide (BEN, Fig 1A). Although exhibiting many of the proper-
ties of fully differentiated β-cells, the resultant cells expressed insulin at only 1% of that in adult
human islets. The present studies aimed at improving the protocol in order to obtain cells that
more closely resembled mature β-cells.
We first investigated whether addition of two other pancreatic (TFs), Nkx6.1 and NeuroD,
would further drive reprogramming towards a more mature β-cell phenotype. These two TFs,
were overexpressed individually or in combination, through recombination deficient adenovi-
ruses along with the original cocktail of Pdx1, MafA, Ngn3 and Pax4 (combination 29, Fig 1A
and 1B). No significant increase in insulin expression was observed upon addition of either
Nkx6.1 or NeuroD to the original cocktail (combinations 13 and 14, Fig 1C). Futhermore, the
original cocktail of Pdx1, Ngn3, MafA and Pax4 [30] was the most efficient in inducing insulin
expression (condition 29, Fig 1B and 1C).
Combinations 20, 24, 25 and 29 were selected for further analysis based on their ability to
induce high insulin mRNA levels (Fig 1C). Interestingly, the original TF combination 29 was
the only able to generate glucose responsive β-like cells (Fig 1D) and the only to induce expres-
sion of the β-cell maturation factor MAFA, indicating that endogenous MAFA expression
might be necessary for the functionality of the reprogrammed β-cells, and that MAFA activa-
tion might be dependent on exogenous Pax4 overexpression, since this TF was absent from
conditions 20, 24 and 25.
Overall, these results suggest that the most efficient TF combination for the ex vivo repro-
gramming of exocrine pancreatic cells towards β-cells results from the concerted actions of
Pdx1, Ngn3, MafA and Pax4. Inclusion of Pax4 appears to be crucial for generating glucose
responsive beta-like cells, as reported previously [41].
Knock-down of endogenous ARX enhances insulin production
In the mouse, during the late stages of pancreatic development, the interplay between the TFs
Arx and Pax4 determines the establishment of either the α- or β-cell lineages (Fig 2A) [38].
Fig 2. ARX knockdown by siRNA improvesmaturation of reprogrammed β-cells. (A) Schematic representation of the
reprogramming protocol. The standard protocol (REP) consisted in plating the exocrine clusters in tissue culture dishes and
allowing them to attach for 48h, followed by 3 day culture in serum free medium (SFM) with 10 μMSB431542 (SB), 2 μMY27632
(Y2), 1 μM 5-Aza-2’deoxycytidine (Aza) and 1 mM sodium butyrate (NaBu). On day 4 cells were transduced with adenoviruses
containing Pdx1, Ngn3, Pax4 and MafA, followed by 7 days in SFM with 1 nM betacellulin, 10 nM exendin-4 and 10 nM
nicotinamide (BEN). The new protocol (REP + siARX) included the transfection with an siRNA targeting ARX at day 6 of the
protocol. (B) Schematic representation of the interplay between the TFs PAX4 and ARX during the late stages of α- and β-cell
development. (C) RT-qPCR analysis of endogenous ARX in untreated (N/A), REP cells, REP cells transfected with a scrambled
siRNA (REP + SCRB) and REP + siARX cells. Expression was normalised to glyceraldehyde 3-phosphate dehydrogenase. Data
are representative of triplicate experiments and represented as mean ± SEM. A one way ANOVA was performed followed by a
Bonferroni post hoc test to compare all treatment groups, where ***P < 0.001, ** P <0.01, *P < 0.05. (D) Immunocytochemistry
for ARX in untreated (N/A), REP cells, REP cells transfected with a scrambled siRNA (REP + SCRB) and REP + siARX cells.
Scale bar = 50 μm. (E)RT-qPCR analysis of insulin, glucagon and somatostatin in untreated (N/A), REP cells, REP cells
transfected with a scrambled siRNA (REP + SCRB), REP + siARX cells, REP + siARX in the absence of exogenous Pax4 (REP
+siARX–PAX4) and in human islets. Expression was normalised to GAPDH. Data are representative of triplicate experiments. A
one way ANOVA was performed followed by a Dunnet post hoc test, ***P < 0.001, ** P <0.01, *P < 0.05. (F) RT-qPCR analysis
of late β-cell markers in untreated (N/A), REP cells, REP cells transfected with a scrambled siRNA (REP + SCRB), REP + siARX
cells, REP + siARX in the absence of exogenous Pax4 (REP+siARX–PAX4) and in human islets. Expression was normalised to
GAPDH. Data are representative of triplicate experiments. A one way ANOVA was performed followed by a Dunnet post hoc test,
***P < 0.001, ** P <0.01, *P < 0.05.
doi:10.1371/journal.pone.0156204.g002
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Moreover, Arx inactivation plays an important role in maintaining β-cell identity in mouse
and human islets [39,40]. Given the crucial role of Pax4 for the functionality of the repro-
grammed β-cells [30,41], we hypothesised that transient knockdown of endogenous ARX
would promote further maturation during reprogramming. These experiments were performed
on laminin-coated plates [42,43] in low glucose (2.5 mM) RPMI [44], which had a moderate
but significant effect on insulin mRNA levels (S2A and S2B Fig). It should be noted that the
antioxidant vitamin C and the vitamin E analogue 6 hydroxy 2,5,7,8 tetramethaylchroman 2
carboxylic acid (Trolox), which can aid in the reprograming of somatic cells towards pluripo-
tency [45,46], as well as the thyroid hormone 3,5,3-triiodo-L-thyronine (T3), which has been
implicated in the maturation of the β-cell lineage [47] and in the reprogramming of exocrine
pancreatic cells towards insulin producing cells [48,49], had no effect on insulin mRNA levels
(S2C Fig).
A pool of four short interfering RNAs directed against ARX was added at day 6 (Fig 2B), i.e.
2 days after addition of the 4 TFs. Under these conditions endogenous ARX mRNA levels
decreased by 50% (Fig 2C and 2D). Reprogramming (REP) in the absence of siARX (Fig 2E)
resulted in insulin mRNA levels of 59.26 ± 11.25 (arbitrary units) and was unaffected by
including a control scrambled siRNA. Reprogramming in the presence of siARX (REP+siARX)
resulted in a significant increase in insulin mRNA levels to 214.30 ± 5.57 (Fig 2E), which was
reproducible between exocrine cells from four additional donors (S2D Fig). The effect of
siARX was dependent on the presence of Pax4 in the reprogramming cocktail (Fig 2E). Expres-
sion of additional key β-cell markers was also increased in REP+siARX as compared to REP
(Fig 2F). Inclusion of siARX significantly decreased glucagon mRNA and protein levels (Fig 2E
and S2E and S2F Fig); however in the absence of Pax4 glucagon mRNA levels increased, thus
emphasising the key inhibitory effect of Pax4 on glucagon expression. While somatostatin
mRNA levels increased significantly by inclusion of siARX (Fig 2E), this was entirely due to
somatostatin expression in very few isolated cells as shown by immunocytochemistry
(S3B Fig).
Glucose sensitivity was markedly enhanced in REP+siARX versus REP, and this effect was
dependent on the presence of exogenous Pax4 (Fig 3A), which supports our previous observa-
tion that Pax4 overexpression is important not only for inducing insulin expression, but also
for the functionality of the reprogrammed insulin-producing cells [41]. In keeping with this
observation, REP+siARX cells expressed mature endocrine markers at levels close to those of
adult islets (Fig 3B). Finally, the timing of endogenous ARX knockdown was crucial. Whereas
knockdown at the later stages of the protocol (Fig 2A) resulted in a significant increase in insu-
lin expression (Fig 2E), the opposite was observed when ARX was inhibited earlier in the proto-
col (Fig 3C and 3D). This is in keeping with studies on the differentiation of hESCs, containing
Fig 3. REP + siARX improves functionality of reprogrammed β-cells. (A) Release of human C-peptide in
static incubation (90 min) in response to low (2.5 mM) and high (20 mM) glucose concentrations. A two way
ANOVA was performed followed by a Bonferroni post hoc test, where ****P < 0.0001. (B) RT-qPCR analysis
of the late functionality markers chromogranin A (CHGA), prohormone convertases (PCSK1 and PCSK2),
glucokinase (GCK), KATP channel subunit SUR1 (SLC30A8) and zinc transporter (ABCC8) in untreated (N/A),
REP+siARX cells and adult islets. Expression was normalised to GAPDH. Data are representative of triplicate
experiments. A one way ANOVA was performed followed by a Dunnet post hoc test. Asterisks on top of bars
represent comparisons with N/A, where *P < 0.05. (C) Schematic representation of the reprogramming
protocol with inclusion of ARX knockdown by siRNA at the early stages (day 3) of the protocol. (D) RT-qPCR
analysis of the three main endocrine hormones insulin (INS), glucagon (GCG) and somatostatin (SST) in
untreated (N/A), REP cells, REP + SCRB (D3) or REP + siARX (D3). Expression was normalised to GAPDH.
Data are representative of triplicate experiments. A one way ANOVA was performed followed by a Dunnet
post hoc test to compare all treatment groups with the control group (N/A), where ***P < 0.001, ** P <0.01,
*P < 0.05.
doi:10.1371/journal.pone.0156204.g003
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a deletion in the ARX gene, which showed a temporal effect of exogenous ARX re-expression
on the resulting endocrine cell population [50].
REP+siARX generates functional β-like cells
Equivalent proportions of C-peptide and insulin, and very low levels of proinsulin were
detected in reprogrammed cells (REP+siARX) and adult human islets, suggesting that proinsu-
lin was efficiently processed to insulin in the reprogrammed cells (Fig 4A). The insulin content
of REP+siARX cells was 14.8±3.2% of the levels present in adult human islets, while REP pro-
duced only 2.4±0.6% of the islet levels (Fig 4A). Electron microscopy confirmed that the newly
reprogrammed REP+siARX β-cells were capable of storing insulin in dense-core granules (Fig
4B and 4C) with a morphology typical of mature β-cells (S3A Fig). High glucose in the culture
medium stimulated the secretion of insulin from REP+siARX cells via mechanisms that are
similar to those in adult human islets; i.e. in a manner that is inhibited in the presence of the
KATP channel activator diazoxide (Fig 4D) and stimulated by the KATP channel blocker tolbuta-
mide (Fig 4E).
Immunocytochemistry showed that REP+siARX cells aggregated in structures with similar
morphology to adult islets, surrounded by MSCs (Fig 4F and S3C Fig). In the reprogrammed
cultures, ~40% of the cells produced C-peptide, while less than 5% of the cells were positive for
glucagon and a very small percentage (<2%) expressed somatostatin (S3B Fig). The small
numbers of somatostatin and glucagon producing cells were found to be monohormonal (Fig
4F). The reprogrammed β-like cells in these clusters were positive for the mature β-cell TFs
MAFA, NKX6.1 and PDX1 (Fig 4F) and did not co-stain with the exocrine markers amylase or
CK19 (S3C Fig). Unlike non-reprogrammed cells (S3D Fig), the reprogrammed β-cells did not
stain positive for the mesenchymal marker vimentin (S3C Fig) or the proliferation marker
Ki67 (Fig 4F), in accordance with the characteristics of adult β-cells.
In summary, these newly reprogrammed cells closely resemble adult β-cells, as they are able
to efficiently store and process insulin, secrete insulin in response to a rise in glucose concen-
trations and contain a large number of the phenotypic characteristics of adult β-cells.
REP+siARX β-cells reverse diabetes in streptozotocin-treated mice
To evaluate their in vivo function, the reprogrammed (REP+siARX) β-like cells were trans-
planted under the kidney capsule of immunocompromised Scid/Beige mice, rendered hyper-
glycaemic by three consecutive doses of streptozotocin (STZ). The reprogrammed cells rescued
diabetes shortly after engraftment, reducing blood glucose to normal physiological levels (Fig
5A) and stabilising body weight (Fig 5B). Human C-peptide was detected in the serum of mice
transplanted with REP+siARX cells after 18 days, the earliest time point after surgery when
this assay could be performed (Fig 5C). Serum human C-peptide levels increased by ~2 fold
after 50 days (Fig 5D). Importantly the levels of circulating human C-peptide of ~6 ng/ml indi-
cate improved functionality when compared with the values observed (0.6 ng/ml) when equiv-
alent numbers of REP cells were grafted into streptozotocin-diabetic NOD/Scid mice in our
previous study [30]. Mice transplanted with non-reprogrammed exocrine cells remained dia-
betic throughout the course of the experiment and no human C-peptide could be detected in
their blood (Fig 5A–5D). An intraperitoneal glucose tolerance test revealed that the repro-
grammed β-cells were functionally similar to endogenous β-cells (Fig 5E). Removal of the
transplanted kidney at the end of the study confirmed that diabetes rescue was due to the pres-
ence of reprogrammed cells, and immunohistochemistry revealed the presence of high num-
bers of monohormonal insulin-producing cells and a small number of glucagon-producing
cells within the grafts, in islet-like structures (Fig 5F).
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In conclusion, the present study has shown that inhibition of ARX plays an important role
in ex vivo reprogramming of exocrine pancreatic cells towards functional β-cells. The repro-
grammed cells resemble mature β-cells in that that are capable of producing significant
amounts of insulin (33.5±7.3 pmol/μg protein) when compared to human islets (226.7±9.5
pmol/μg protein), are glucose responsive, phenotypically stable, and are capable of rescuing
diabetes in an in vivo setting.
Discussion
Over 95% of the exocrine pancreas is discarded following each islet isolation procedure. The
ability to reprogramme this tissue towards functional β-cells could circumvent the need for
multiple donor pancreata to treat a single patient and would allow one pancreas to treat several
patients. In fact we have previously shown that the discarded exocrine material could be repro-
grammed towards β-like cells. However, these cells produced insulin levels well below those
found in adult human islets [30]. Here we report the ex vivo generation from human exocrine
pancreas of mature functional, i.e. glucose responsive, β-cells that contain insulin at levels
around 15–30% of those in human islets. These cells would have an immediate therapeutic
effect if implanted in patients with type 1 diabetes. We know this from the fact that in type 1
diabetes there is a progressive loss of β-cells that occurs over a number of years before the onset
of symptoms, such that at clinical presentation most patients have residual (~10%) β-cell func-
tion [37]. This suggests that reinstating a fraction of the normal β-cell mass would have a thera-
peutic effect. Moreover, successful transplants can be achieved with donor islets equivalent to
as little as 30–40% of the total islet content of a pancreas.
The reprogrammed β-like cells were monohormonal and formed islet-like structures with
few glucagon- and somatostatin-expressing cells. The reprogrammed cells efficiently processed
proinsulin to insulin, contained insulin storage granules, secreted insulin in response to glu-
cose, and rescued diabetes in a streptozotocin mouse model. The diabetic mouse studies con-
firmed that the cells were phenotypically stable. The protocol was crucially dependent on
overexpressing exogenous Pax4 and, at a later stage inhibiting endogenous ARX. The antago-
nistic roles of Arx and Pax4 have been well documented in pancreatic development in mice.
Thus, Pax4 inhibits Arx expression in β-cells, while the reverse occurs for α-cell differentiation.
Moreover, the Arx promoter is hypermethylated in adult β-cells [39] and Arx overexpression
results in conversion of adult human β-cells towards α-cells [51]. We have previously shown
that Pax4 plays a crucial role in generating functional β-cells [30,41], but the exact mechanisms
are unclear.
With regard to the mechanisms, we have previously shown that successful TF-mediated
conversion of pancreatic exocrine cells to β-like cells is dependent on suppressing, via inhibi-
tion of Rho Kinase and TGFβ1 signalling, the EMT that pancreatic tissue undergoes when
placed in monolayer culture [30]. EMT is a multi-stage process [52] and it is likely that our
protocol involves delaying transit through an early stage. During this early stage, amylase-posi-
tive cells disappear through an intermediate that co-expresses amylase and the ductal marker
CK19 [25,30]. Further mechanistic studies at the single cell level will be required to ascertain
whether this acinar/ductal hybrid cell is the source of the resultant β-like cells. In vivo studies
in mice have shown that exogenous Pdx1, MafA and Ngn3 can induce the appearance of new
Fig 4. REP + siARX closely resemble adult β-cells. (A) Human proinsulin, insulin and C-peptide content of untreated (N/A), REP+siARX,
REP cells and human islets, normalised to total protein content. (B) Electron microscopy of REP + siARX cells. Scale bar = 2 μm (top left),
0.5 μm (right) and 0.1 μm (bottom right). (C) Immunogold labelling of insulin granules in REP + siARX cells. Scale bar = 0.5 μm. (D-E)
Human C-peptide release under different secretory conditions. A one way ANOVA was performed followed by a Dunnet post hoc test,
**P < 0.01. (F) Immunocytochemistry of REP+siARX cells. Scale bar = 20 μm.
doi:10.1371/journal.pone.0156204.g004
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β-cells within the pancreas. Furthermore, genetic lineage tracing studies demonstrated that
these newly formed isolated β-cells likely arose through transdifferentiation of acinar cells [24].
It will be interesting to know if this transdifferentiation also occurred via an acinar/ductal
intermediate.
The final protocol (Fig 6) takes around 12 days and involves plating the isolated human exo-
crine tissue on laminin and culturing in media containing 2.5 mM glucose. Initially, the EMT
is inhibited using Rho kinase and TGF-β inhibitors in combination with methyltransferase and
histone deacetylase inhibitors. This is followed by transduction with the exogenous TFs Pdx1,
Ngn3, Pax4 and MafA in media containing betacellulin, nicotinamide and exendin-4. Inhibi-
tion of endogenous ARX by siRNA is performed towards the final stages of the protocol. The
final product is around 40% endocrine; the remaining cells are pancreatic MSCs which have
added advantage in terms of the function of the transplanted tissue [53–55]. The cells are stable
as evidenced by the prolonged appearance of human C-peptide in the blood of transplanted
mice and the morphology of the transplanted aggregates at periods up to 100 days after
transplantation.
In terms of the clinical applications of this protocol, there are at least five important criteria
that would need to be met; 1. Do the cells express fully processed insulin at therapeutic levels?
2. Do the cells function, i.e. efficiently store, process and secrete insulin in response to glucose
and other nutrients, in a manner similar to adult human islets? 3. Do the cells form aggregates
that look like adult human islets? 4. Do the cells normalise blood glucose levels in an appropri-
ate diabetic animal model? 5. Are the cells phenotypically stable? As described above our proto-
col meets all five of these criteria. It would therefore be interesting to compare this protocol
with other approaches to obtaining an alternative supply of islets for transplantation. Such a
goal, however, is hindered by the lack of quantitative data in most of the relevant studies. Many
studies to date have relied heavily on RT-qPCR, immunocytochemistry and flow cytometry.
Where the quantitative data are available our reprogrammed cells that make 33.5 pmol insulin/
μg protein compare well with the functionality of human pluripotent cell (hPC)- derived islet
Fig 5. REP + siARX cells rescue diabetes in Streptozotocin-treated mice. Blood glucose levels (A), percentage of body weight loss (B), serum human C-
peptide levels (C-D), and intraperitoneal glucose tolerance test (E) of diabetic mice grafted with 5 X 106 REP+siARX cells (n = 5), non-reprogrammed
exocrine cells (n = 6) and control non diabetic and non-grafted mice (n = 6). STZ—streptozotocin administration; Tx—time of surgery; Nephrectomy—time of
graft removal. Serum samples were collected after 4h starvation (Fast) or ad libitum feeding (Fed) for C-peptide detection. A two way ANOVA was performed
followed by a Bonferroni post hoc test, ****P < 0.0001. (F) Immunostaining for C-peptide and glucagon in REP+siARX grafts. Nuclei were counterstained
with DAPI. Scale bar = 50 μm.
doi:10.1371/journal.pone.0156204.g005
Fig 6. Final reprogramming protocol. Schematic representation of the final reprogramming protocol. The cells are plated in laminin-coated dishes
for 48h (Stage 1). The cells are then cultured in serum free RPMI medium (SFM) containing 2.5 mM glucose. For the first 3 days (Stage 2), EMT is
inhibited using Rho kinase (2 μMY27632) and TGF-β (10 μMSB431542) inhibitors in combination with methyltransferase (1 μM 5’-Aza-2’-
deoxycytidine) and histone deacetylase inhibitors (1 mM sodium butyrate). This is followed by transduction with the exogenous TFs (Stage 3) Pdx1,
Ngn3, Pax4 and MafA and culture in SFM containing 1 nM betacellulin, 10 mM nicotinamide and 10 nM exendin-4. Inhibition of endogenous ARX by
siRNA is performed at day 6 (Stage 4) and the cells are then maintained in SFM containing BEN until day 10 (Stage 5).
doi:10.1371/journal.pone.0156204.g006
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progenitors β-cells [5], with the insulin content and functionality of hPC-derived fully differen-
tiated β-like cells [10,11], and with β-like cells generated from human ductal-enriched cells
[28].
In summary, our protocol generates β-cells that share many of the properties of adult
endogenous β-cells and compare well with surrogate β-cells generated from hPCs. Our
approach, however, has the advantage that the cells are not at any stage pluripotent, which has
important safety considerations. In addition, our protocol is relatively simple, cost effective,
adaptable to clinical grade good manufacturing (GMP) conditions, and at 12 days is signifi-
cantly shorter than the time required to generate fully functional β-like cells from hPCs. We
estimate that around 3–5 x 108 reprogrammed cells would have a therapeutic effect if trans-
planted in diabetic patients; thus one donor pancreas could provide numerous (~10–12) islet
grafts.
Supporting Information
S1 Fig. Delaying EMT does not preserve contaminating β-cells in culture. Expression of
endocrine markers present in the initial exocrine tissue (-48h) is quickly lost after 48h in cul-
ture. EMT inhibition with SB, Y2, Aza and NaBu does not lead to re-expression of any of the
endocrine hormones. At the same time, amylase expression is lost while the treatment results
in the increase of the ductal marker CK19 and E-cadherin, supporting our previous observa-
tion of an existing intermediate amylase+/CK19+ cell population. (A) RT-qPCR analysis of
endocrine and exocrine pancreatic markers at time points during the first five days of the
reprogramming protocol. Expression was normalised to GAPDH. Data are representative of
triplicate experiments. A one way ANOVA was performed followed by a Dunnet post hoc test,
where P< 0.001,  P<0.01 and P< 0.05. (B) Immunocytochemistry for C-peptide and
the exocrine marker CK19 during the first 72h of the reprogramming protocol. Nuclei were
counterstained with 4',6-Diamidino-2-Phenylindole, Dihydrochloride (DAPI). Scale
bar = 100 μm.
(TIF)
S2 Fig. Laminin, low glucose and siARX favour β-cell reprogramming. (A) Laminin is the
extracellular matrix component most favourable to endocrine reprogramming, resulting in
increased expression levels of the three main pancreatic hormones insulin (INS), glucose
(GCG) and somatostatin (SST). RT-qPCR analysis of insulin, glucagon and somatostatin in
reprogrammed cells (REP) cultured in standard tissue culture dishes (CTRL) or dishes coated
with extracellular matrix components, normalised to GAPDH. A two way ANOVA was per-
formed followed by a Bonferroni post hoc test, P< 0.001,  P<0.01, P< 0.05. (B) Low
glucose concentrations favoured insulin expression under reprogramming conditions, in con-
trast to higher glucose concentrations. RT-qPCR analysis of insulin, glucagon and somatostatin
in N/A and REP cultured in various glucose concentrations, normalised to GAPDH. Data are
representative of triplicate experiments. A two way ANOVA was performed followed by a Bon-
ferroni post hoc test, P< 0.001,  P<0.01, P< 0.05. (C) Antioxidant compounds and thy-
roid hormone 3,5,3-triiodo-L-thyronine (T3) do not enhnance reprogramming towards the
beta-cell lineage. RT-qPCR analysis of insulin, glucagon and somatostatin in N/A and REP cul-
tured in the presence of several combinations of the antioxidants Vitamin C (10 μg/mL, Vit.
C), Trolox (5 μM) and the thyroid hormone T3 (1 μM). Data are normalised to GAPDH and
representative of triplicate experiments. A two way ANOVA was performed followed by a Bon-
ferroni post hoc test, P< 0.001,  P<0.01, P< 0.05. (D) The reprogramming protocol is
highly reproducible between exocrine preparations of distinct donors. RT-qPCR analysis of
insulin following REP + siARX reprogramming in exocrine preparations from four distinct
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donors. (E) Inhibition of Arx decreases reprogramming towards glucagon-producing cells.
Human glucagon content of untreated (N/A), REP, REP+siARX cells and human islets, nor-
malised to total protein. (F) Immunostaining for glucagon and C-Peptide on REP and REP
+ siARX cells. Nuclei were counterstained with 4',6-Diamidino-2-Phenylindole, Dihydrochlor-
ide (DAPI). Scale bar = 20 μm.
(TIF)
S3 Fig. REP+siARX mainly generates insulin producing cells. (A) Immunogold labelling of
insulin granules in adult human islets. Scale bar = 0.05 μm. (B) Reprogramming generates 40%
beta-like cells and less than 5% of other endocrine cell types. Immunocytochemistry for the
three main pancreatic hormones after REP+siARX reprogramming. Nuclei were counter-
stained with 4',6-Diamidino-2-Phenylindole, Dihydrochloride (DAPI). Scale bar = 50 μm.
Immunohistochemical quantification for each endocrine cell type. Data is represented as mean
+ standard error of the mean, where  P<0.01. Five hundred cells were quantified from 5 dif-
ferent random field views for each replicate. (C) Reprogrammed cells do not co-express exo-
crine or mesenchymal markers. Immunocytochemistry in REP+siARX cells for insulin or C-
peptide and the exocrine markers CK19 and amylase, and the mesenchymal marker vimentin.
Nuclei were counterstained with 4',6-Diamidino-2-Phenylindole, Dihydrochloride (DAPI).
Scale bar = 20 μm. (D)Non-reprogrammed cells dedifferentiate towards mesenchymal stromal
cells and proliferate in culture. Immunocytochemistry for vimentin, C-peptide and ki67 of
untreated exocrine cultures. Nuclei were counterstained with 4',6-Diamidino-2-Phenylindole,
Dihydrochloride (DAPI). Scale bar = 20 μm.
(TIF)
S1 Table. List of TaqMan probes used for RT-qPCR analysis.
(DOCX)
S2 Table. List of primary antibodies used for immunocytochemistry.
(DOCX)
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